Skip to content

    LIGAND PHARMACEUTICALS (LGND) stock price & financials

    View LGND earnings calls

    Overview

    Price

    Market Cap

    Sector

    Rank

    Performance+76.3% 1Y

    Financials

    Income Statement

    Financial Trajectories

    11
    Quarterly
    MetricQ3 FY24Q4 FY24Q1 FY25Q2 FY25Q3 FY25Q4 FY25Q1 FY26Q2 FY26Trend
    EarningsRevenue
    $51.81M
    $42.81M
    $45.33M
    $47.63M
    $115.46M
    +122.8%
    $59.67M
    +39.4%
    $51.72M
    +14.1%
    $63.69M
    +33.7%
    Strengthening
    Operating Profit
    $3.14M
    -$9.64M
    -$36.22M
    $8.44M
    $54.93M
    +1647.7%
    $13.84M
    $17.37M
    $8.59M
    +1.7%
    Stable
    Net Profit
    -$7.17M
    -$31.09M
    -$42.45M
    $4.85M
    $117.27M
    $44.78M
    -$13.35M
    +68.6%
    $48.51M
    +900.8%
    Strengthening
    EPS
    $-0.39
    $-2.21
    $0.25
    $5.99
    $-0.67
    +69.7%
    $2.42
    +868.0%
    Strengthening
    Other Income
    -$9.48M
    -$29.56M
    -$13.96M
    $2.78M
    $86.21M
    $42.94M
    -$41.63M
    -198.1%
    $55.71M
    +1904.8%
    Strengthening
    Interest
    $741.0K
    $887.0K
    $867.0K
    $1.15M
    $910.0K
    +22.8%
    $1.78M
    +101.2%
    $1.75M
    +101.5%
    $1.75M
    +51.6%
    Strengthening
    Depreciation
    Profit before Tax
    -$6.34M
    -$39.20M
    -$50.18M
    $11.22M
    $141.14M
    $56.78M
    -$24.26M
    +51.7%
    $64.30M
    +473.0%
    Strengthening
    MarginsOPM
    6.1%
    -22.5%
    -79.9%
    17.7%
    47.6%
    +683.9%
    23.2%
    33.6%
    13.5%
    -23.9%
    Weakening
    Tax
    -13.1%
    20.7%
    15.4%
    56.8%
    16.9%
    21.1%
    +2.1%
    45.0%
    +192.1%
    24.6%
    -56.8%
    Strengthening
    ReturnsROIC
    -1.2%
    -5.3%
    -7.3%
    0.8%
    20.1%
    7.7%
    -2.3%
    +68.6%
    8.3%
    +900.8%
    Strengthening

    Balance Sheet

    Balance Sheet

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    AssetsCash & Equivalents$117.16M$71.54M$47.62M$19.52M$45.01M$22.95M$72.31M$174.93M$1.01B
    Short-Term Investments
    Total Current Assets$870.54M$1.12B$500.56M$464.75M$263.60M$237.43M$331.56M$832.27M$1.46B
    Net PP&E$5.37M$17.54M$20.08M$16.40M$23.40M$21.67M$22.04M$10.79M$9.84M
    Goodwill$86.65M$95.23M$189.66M$105.67M$0$103.37M$105.25M$101.54M$101.54M
    Intangibles$219.79M$210.45M$595.33M$376.69M$342.45M$299.61M$266.65M$225.44M$209.24M
    Total Assets$1.26B$1.49B$1.36B$1.30B$762.67M$787.22M$941.77M$1.56B$2.19B
    LiabilitiesTotal Current Liabilities$82.25M$17.00M$100.11M$41.66M$98.81M$16.78M$37.11M$37.45M$46.74M
    Short-Term Debt
    Long-Term Debt$1.13B
    Long-Term Leases$0$9.97M$5.64M$2.26M$10.34M$5.75M$5.82M$4.20M$3.78M
    Total Liabilities$699.89M$727.68M$652.76M$476.43M$165.18M$86.30M$111.33M$543.42M$1.22B
    EquityCommon Stock & APIC$21.0K$17.0K$16.0K$17.0K$17.0K$18.0K$20.0K$20.0K$20.0K
    Retained Earnings-$229.20M$400.11M$391.95M$449.09M$450.86M$503.02M$498.98M$608.09M$583.25M
    Total Equity$560.91M$767.23M$709.52M$821.16M$597.49M$700.91M$830.44M$1.02B$967.52M
    HighlightsNet Cash / (Debt)

    Cash Flow

    Cash Flow

    USD · Annual
    Line itemFY18FY19FY20FY21FY22FY23FY24FY25TTM
    ActivitiesCash from Operating$194.06M-$29.34M$54.59M$78.80M$137.85M$49.58M$97.05M$49.36M$131.71M
    Cash from Investing-$423.27M$466.92M$231.65M$30.52M$163.62M-$11.68M-$143.66M-$377.32M-$144.78M
    Cash from Financing$328.58M-$485.17M-$310.55M-$137.76M-$275.99M-$59.95M$97.14M$428.22M$950.28M
    SummaryCapital Expenditure-$887.0K-$2.55M-$4.46M-$8.76M-$17.92M-$3.52M-$1.82M-$452.0K-$278.0K
    Free Cash Flow$193.17M-$31.89M$50.13M$70.04M$119.93M$46.06M$95.23M$48.91M$131.44M
    FCF Margin76.8%-26.5%30.6%29.0%61.1%35.1%57.0%18.2%45.2%

    Ratios